Literature DB >> 24868030

Adjuvant chemotherapy in older women with breast cancer: who and what?

Hyman B Muss1.   

Abstract

A 73-year-old woman has been diagnosed with a mammographically detected grade 3, 2.2-cm invasive ductal carcinoma that is sentinel lymph node negative, estrogen receptor positive (80%), progesterone receptor negative, and human epidermal growth factor receptor 2 negative (0 by immunohistochemistry). A gene expression assay (Oncotype DX, Genomic Health, Redwood City, CA) showed a recurrence score of 28. Except for well-controlled hypertension and some aches and pains in her hands and knees, she has no other major illnesses. Her medications include an antihypertensive, vitamin D, and calcium. She discontinued cigarette smoking 20 years ago and has an occasional glass of wine. She describes her health as good, is fully functional, drives, has had no falls, and provides the majority of care for her sick husband. Her blood pressure is 146/88, her body mass index is 29.7, and her physical examination is normal. She is aware of the benefits and risks of adjuvant endocrine therapy and has been referred to discuss the role of chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24868030     DOI: 10.1200/JCO.2013.54.8586

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  6 in total

Review 1.  Long term side effects of adjuvant chemotherapy in patients with early breast cancer.

Authors:  Jessica J Tao; Kala Visvanathan; Antonio C Wolff
Journal:  Breast       Date:  2015-08-20       Impact factor: 4.380

2.  Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells.

Authors:  Dinesh Vyas; Nicolas Lopez-Hisijos; Sulakshana Gandhi; M El-Dakdouki; Marc D Basson; Mary F Walsh; X Huang; Arpita K Vyas; Lakshmi S Chaturvedi
Journal:  J Nanosci Nanotechnol       Date:  2015-09

3.  Impact of Guideline-Discordant Treatment on Cost and Health Care Utilization in Older Adults with Early-Stage Breast Cancer.

Authors:  Courtney P Williams; Kelly M Kenzik; Andres Azuero; Grant R Williams; Maria Pisu; Karina I Halilova; Stacey A Ingram; Supriya K Yagnik; Andres Forero; Smita Bhatia; Gabrielle B Rocque
Journal:  Oncologist       Date:  2018-08-17

4.  Evaluation of whether adjuvant chemotherapy can be safely omitted for older female patients with ER-positive, HER2-negative N1 breast cancer: a study based on the SEER database.

Authors:  Minhao Lv; Peng Yuan; Youzhao Ma; Peiqi Tian; Xiuchun Chen; Zhenzhen Liu
Journal:  Ann Transl Med       Date:  2021-07

5.  Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer.

Authors:  Doris van Abbema; Pauline Vissers; Judith de Vos-Geelen; Valery Lemmens; Maryska Janssen-Heijnen; Vivianne Tjan-Heijnen
Journal:  Cancers (Basel)       Date:  2019-08-23       Impact factor: 6.639

6.  Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503).

Authors:  Gretchen G Kimmick; Brittny Major; Jonathan Clapp; Jeff Sloan; Brandelyn Pitcher; Karla Ballman; Myra Barginear; Rachel A Freedman; Andrew Artz; Heidi D Klepin; Jacqueline M Lafky; Judith Hopkins; Eric Winer; Clifford Hudis; Hyman Muss; Harvey Cohen; Aminah Jatoi; Arti Hurria; Jeanne Mandelblatt
Journal:  Breast Cancer Res Treat       Date:  2017-03-10       Impact factor: 4.872

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.